Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia

Psychiatry and Clinical Neurosciences

Volumn 68, Issue 9, 2014, Pages 692-700

  Tsai, Chon Haw ^a,b,c   Huang, Hui Chun ^a,c   Liu, Bey Ling ^a   Li, Chia Ing ^a   Lu, Ming Kuei ^a,c   Chen, Xianxiu ^a,b   Tsai, Mu Chieh ^d   Yang, Yu Wan ^a,c   Lane, Hsien Yuan ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

dementia; hallucination; N methyl D aspartate; neuropsychiatry; Parkinson's disease

Indexed keywords

GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; SARCOSINE;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HAMILTON SCALE; HUMAN; MALE; MOTOR PERFORMANCE; NEUROPSYCHIATRY; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; VERY ELDERLY; AGONISTS; COMPLICATION; MIDDLE AGED; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DEMENTIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RECEPTORS, N-METHYL-D-ASPARTATE; SARCOSINE; TREATMENT OUTCOME;

EID: 84906934165     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12175     Document Type: Article

References (30)

1. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord. 2007; 22: 1689-1707. Quiz 837. (Pubitemid 47597592)
2. Almaraz AC, Driver-Dunckley ED, Woodruff BK, et al. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. Neurologist 2009; 15: 234-237.
3. Lane HY, Liu YC, Huang CL, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study. Biol. Psychiatry 2008; 63: 9-12.
4. Huang CC, Wei IH, Huang CL, et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol. Psychiatry 2013; 74: 734-741.
5. Kalia LV, Kalia SK, Salter MW,. NMDA receptors in clinical neurology: Excitatory times ahead. Lancet Neurol. 2008; 7: 742-755. (Pubitemid 351957932)
6. Lipton SA, Rosenberg PA,. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 1994; 330: 613-622.
7. Lin CH, Lane HY, Tsai GE,. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol. Biochem. Behav. 2012; 100: 665-677.
8. Coyle JT, Puttfarcken P,. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262: 689-695. (Pubitemid 23350687)
9. Gibb WR, Lees AJ,. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1988; 51: 745-752.
10. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE,. Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 2005; 62: 1196-1204. (Pubitemid 41586919)
11. Hoehn MM, Yahr MD,. Parkinsonism: Onset, progression and mortality. Neurology 1967; 17: 427-442.
12. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J,. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314. (Pubitemid 24382728)
13. Rahman S, Griffin HJ, Quinn NP, Jahanshahi M,. Quality of life in Parkinson's disease: The relative importance of the symptoms. Mov. Disord. 2008; 23: 1428-1434.
14. Beck AT, Steer RA, Ball R, Ranieri W,. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J. Pers. Assess. 1996; 67: 588-597. (Pubitemid 26382973)
15. Hamilton M,. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960; 23: 56-62.
16. Sclan SG, Saillon A, Franssen E, Hugonot-Diener L, Saillon A, Reisberg B,. The behavior pathology in Alzheimer's disease rating scale (BEHAVE-AD): Reliability and analysis of symptom category scores. Int. J. Geriatr. Psychiatry 1996; 11: 819-830. (Pubitemid 26331858)
17. Studenski S, Hayes RP, Leibowitz RQ, et al. Clinical Global Impression of Change in Physical Frailty: Development of a measure based on clinical judgment. J. Am. Geriatr. Soc. 2004; 52: 1560-1566. (Pubitemid 39209608)
18. Teng EL, Hasegawa K, Homma A, et al. The Cognitive Abilities Screening Instrument (CASI): A practical test for cross-cultural epidemiological studies of dementia. Int. Psychogeriatr. 1994; 6: 45-58; discussion 62. (Pubitemid 24167129)
19. Homma A, Meguro K, Dominguez J, Sahadevan S, Wang YH, Morris JC,. Clinical dementia rating workshop: The Asian experience. Alzheimer. Dis. Assoc. Disord. 2006; 20: 318-321. (Pubitemid 44900951)
20. Frye MA, Tsai GE, Huggins T, Coyle JT, Post RM,. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol. Psychiatry 2007; 61: 162-166. (Pubitemid 46072777)
21. Malkesman O, Austin DR, Tragon T, et al. Acute d-serine treatment produces antidepressant-like effects in rodents. Int. J. Neuropsychopharmacol. 2012; 15: 1135-1148.
22. Zarate CA, Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006; 63: 856-864. (Pubitemid 44188478)
23. Gelfin E, Kaufman Y, Korn-Lubetzki I, et al. d-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease. Int. J. Neuropsychopharmacol. 2012; 15: 543-549.
24. Zarowitz BJ,. Prevalence of antipsychotic use in long-term care residents with Parkinson dementia. Geriatr. Nurs. 2012; 33: 217-219.
25. Burghaus L, Eggers C, Timmermann L, Fink GR, Diederich NJ,. Hallucinations in neurodegenerative diseases. CNS Neurosci. Ther. 2012; 18: 149-159.
26. Heresco-Levy U, Shoham S, Javitt DC,. Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: A hypothesis. Mov. Disord. 2013; 28: 419-424.
27. Yoshikawa S, Oguchi T, Funahashi Y, de Groat WC, Yoshimura N,. Glycine transporter type 2 (GlyT2) inhibitor ameliorates bladder overactivity and nociceptive behavior in rats. Eur. Urol. 2012; 62: 704-712.
28. Martineau M, Baux G, Mothet JP,. d-serine signalling in the brain: Friend and foe. Trends Neurosci. 2006; 29: 481-491. (Pubitemid 44118443)
29. Panatier A, Theodosis DT, Mothet JP, et al. Glia-derived d-serine controls NMDA receptor activity and synaptic memory. Cell 2006; 125: 775-784.
30. Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am. J. Psychiatry 2012; 169: 71-79.